Clinical Trial

Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm(CVS) is closely related to delayed cerebral ischemia (DCI), which is one of the important reasons for poor outcomes in patients with aSAH. In recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.
Trial Details
NCT Number NCT07652749
Lead Sponsor Beijing Tiantan Hospital
Conditions Aneurysmal Subarachnoid Hemorrhage, Stellate Ganglion Block, Neurological Prognosis
Enrollment 560 participants
Start Date 2026-06-15
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17